Gene editing techniques may eventually allow trisomy to be treated at the cellular level, according to an in vitro ...

The global Gene Editing Market was valued at $5.1 billion in 2022 and is projected to reach $16.2 billion by 2030, growing at ...

When the gene editing tool CRISPR-Cas9 rocketed to fame more than a decade ago, it transformed biotechnology. Faster, cheaper, and safer than previous methods, the tool helped scientists gain insight ...

In the spring, five patients with sickle cell disease began treatment with Casgevy, the first FDA-approved CRISPR-Cas9 gene editing treatment. The therapy—which involves removing blood stem ...

The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Mammoth Biosciences researchers have developed NanoCas, an ultracompact CRISPR nuclease, demonstrating its ability to perform ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

By Balambal Suryanarayanan CRISPR-Cas9 is a repurposed gene editing tool that allows scientists to cut, replace, and insert pieces of DNA in precise regions along the strand. Courtesy of NIH Image ...

Researchers developed a new gene-editing strategy that dramatically boosts the effectiveness of gene therapies in the liver, a breakthrough that could lead to new treatments for about 700 genetic ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...